The present invention relates to, inter alia, engineered bacteria expressing (i) a surface protein, which specifically interacts cell membrane receptors that are exposed to the luminal side of epithelial cells of diseased gastrointestinal tissue and/or epithelial tissue lining the bile duct, pancreatic duct, or common bile duct, etc., and (ii) a detection marker. The engineered bacteria of the present technology are useful for detecting diseased gastrointestinal tissue and/or epithelial tissue lining the bile duct, pancreatic duct, or common bile duct, etc.

Embodiments of the disclosure include universal antigen-specific T cell compositions, and methods of making and using the same. Embodiments of the disclosure also include methods of identifying and selecting suitable donors for use in constructing donor minibanks of antigen-specific T cell lines; donor minibanks of antigen-specific T cell lines; universal antigen-specific T cell compositions comprising a plurality of the antigen specific T cell lines from such donor minibanks, and donor banks made up of a plurality of such minibanks. The present disclosure includes methods of treating a disease or condition comprising administering to a patient at least one universal antigen-specific T cell composition disclosed herein.

The present disclosure provides methods for the identification, characterization and ranking of putative tau monomer stabilizing agents. Specifically, the disclosure provides methods for assessing the capability of a test compound to stabilize a tau monomer, methods of prioritizing a plurality of test compounds from a library identified as tau monomer stabilizing agents, methods of screening a test compound library to identify tau monomer stabilizing agents, and a kit providing the reagents to perform the described methods.

The invention provides a natural killer cell, NK-92, modified to express an Fc receptor on the surface of the cell, such as CD16 (FcγRIII-A), or other Fcγ or Fc receptors. The modified NK-92 cell can be further modified to concurrently express an associated accessory signaling protein, such as FcεRI-γ,TCR-ζ, or to concurrently express interleukin-2 (IL-2) or other cytokines. Additional methods are disclosed for various assays, assessments, and therapeutic treatments with the modified NK-92 cells.

The disclosure provides for compositions, methods, and kits for evaluating the effect of a cell-killing agent on a population of tumor cells (e.g., tumor cells that can inducibly express reporter protein).

The present invention relates to a method for diagnosing and treating atherosclerosis by using nanovesicle targeting a site of change in blood flow, and more specifically, the present invention provides a stem cell-derived nanovesicle, which is an anti-atherosclerosis diagnosis and treatment platform using a peptide capable of targeting a disturbed blood flow, wherein the nanovesicle provides strong anti-inflammatory and pre-endothelial recovery effects similar to that of a mesenchymal stem cell, and thus it can be used as a new diagnosis and treatment agent capable of preventing the onset of atherosclerosis.

Provided herein are compositions, systems, kits, and methods that employ a colitic induced human colitic organoid (iHCO) that has both an epithelial compartment and mesenchymal compartment, and provides at least one feature (e.g., leaky epithelial barrier) of IBD patient tissue (e.g., ulcerative colitis or Crohn's disease tissue). In certain embodiments, such iHCO's are employed in vitro or in vivo to screen candidate IBD treating compounds (e.g., to determine effectiveness for a particular patient who was the source of the original colonic fibroblasts used to generate the iHCO).

The present invention provides novel processes, compositions, and methods for analyzing or assaying the potency and/or functionality of tumor infiltrating lymphocyte (TIL) products for use in therapy, including human cancer therapy, and analyzing or assaying the potency and/or functionality of other polyclonal products, such as marrow infiltrating lymphocyte (MIL) and peripheral blood lymphocyte (PBL) products. Compositions, methods, and kits for preparing and treating cancer using TIL, MIL, and PBL products are also provided.

The present disclosure provides a composition containing a purified and enriched population of potent exosomes derived from extracellular vesicles derived from mesenchymal stem cells (MSCs), a method for diagnosing a human subject aged over 50 years with an age-related chronic disease characterized by disease related dysfunction and optimally treating the subject, and a method for reprogramming a donated organ or tissue comprising a fibrotic disposition including treating the donated organ or tissue with a composition comprising purified enriched population of potent exosomes derived from extracellular vesicles derived from MSCs of a normal healthy subject.

A method is disclosed for acquiring a single, in-focus two-dimensional projection image of a live, three-dimensional cell culture sample, with a fluorescence microscope. One or more long-exposure “Z-sweep” images are obtained, i.e. via a single or series of continuous acquisitions, while moving the Z-focal plane of a camera through the sample, to produce one or more two-dimensional images of fluorescence intensity integrated over the Z-dimension. The acquisition method is much faster than a Z-stack method, which enables higher throughput and reduces the risk of exposing the sample to too much fluorescent light. The long-exposure Z-sweep image(s) is then input into a neural network which has been trained to produce a high-quality (in-focus) two-dimensional projection image of the sample. With these high-quality projection images, biologically relevant analysis metrics can be obtained to describe the fluorescence signal using standard image analysis techniques, such as fluorescence object count and other fluorescence intensity metrics (e.g., mean intensity, texture, etc.).